retatrutide phase 2 weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Survodutide vs. Retatrutide for Weight

It's a once-daily oral GLP-1 receptor agonist, and in June 2026 its first big obesity trial was published in The Lancet

Knowing how it works, lets discuss the dosage and method of administering semaglutide

Other notable trials in this space include the LEADER trial (liraglutide), the SUSTAIN-6 trial (semaglutide), and the REWIND trial (dulaglutide)

Histamine-2 receptor antagonists (H2RAs) such as famotidine, cimetidine, or nizatidine offer a less potent but reasonable alternative

Shaking can damage cagrilintide

Storage guidance must specify refrigeration range and beyond use dating, and the pharmacy should document how cold chain is maintained during shipping